An early-stage healthcare technology venture capital investment firm based in Boston raised $200 million for its first dedicated healthcare technology-focused fund. The firm primarily invests in companies in the seed, Series A and B stages targeting healthcare technology and services and is seeking 8-10 new investments within the next year. The firm typically invests an initial range of $1-8M and may go up to investing $20M per company overall, though the size may vary depending on the opportunity. The firm primarily invests in companies based in the US, though is open to companies on a global level. The firm seeks to be a significant investor in any of its portfolio companies and will often serve on the boards of those companies.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and services sectors with a specific focus on healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare and leverage wireless, data and analytics technologies. The firm currently is not focused on therapeutics or medical device investment opportunities, though has interest in medical devices with a software/data component, such as sensors. The firm may be open to 510K devices, however, it is not interested in regulated devices. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech sector investment firm headquartered in China opened a Boston office and raised a USD investment fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to help its portfolio companies reach key value-added milestones. The firm will consider opportunities based in China and North America. Companies with a strong China angle or involvement are their sweet spot.

The firm focuses mostly on therapeutics, and also open to Diagnostics. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture capital arm of a US health system looks to invest between $500K-$5M, in Seed, Series A and Series B rounds. The firm is looking to invest in technologies that can be leveraged by a large healthcare system. The group is currently looking for opportunities throughout the United States.

The girm is looking to invest in companies with strong ROI potential that also are strategically aligned with the group’s parent healthcare system. The firm is interested in companies meeting this criteria operation in the digital health, medical devices and diagnostics. The firm is open to investing in companies that are pre-revenue, including those with a product still in development or in clinical trials. The firm does not invest in therapeutics or Class III medical devices.

The firm is looking for companies with experienced management teams and generally seeks board representation following investment. The group is also interested in forming joint-ventures or co-development programs when relevant and looks to leverage its connection to the health system to aid companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporation headquartered in Tokyo, Japan with additional offices in California is interested in R&D and venture funding of new companies. Typical allocation sizes range from $0.2M-$2M, and may be structured as research funds, equity, or convertible loans depending on the phase of development. The firm will consider companies at all stages from concept to OTM, with OTM products being candidates for M&A and distribution agreements. Investments are focused on medical technology and diagnostics companies.

The firm is interested in medical technology and diagnostics companies across indications, but has a current focus in cardiovascular and regenerative indication areas.

The firm may or may not seek a board seat on companies they invest in. They are open to working with all management teams, and view deals globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.